ImpediMed

ImpediMed is a global medical technology company based in Brisbane, Australia, with operations in the United States and Europe. The company specializes in designing and manufacturing medical devices that utilize bioimpedance spectroscopy (BIS) technology for noninvasive clinical assessment and monitoring of fluid status and tissue composition in patients. ImpediMed focuses on addressing secondary lymphedema, particularly breast cancer-related lymphedema, as well as conditions like heart failure and protein calorie malnutrition. The flagship product, the SOZO® Digital Health Platform, is FDA-cleared and CE-marked, providing accurate, non-invasive measurements to enable early detection and management of lymphedema. SOZO integrates with electronic health records for efficient care coordination. ImpediMed also offers devices like the SFB7 for research and ImpediVET for veterinary applications. The company provides medical devices, consumables, software subscription services, and a secure cloud-based platform for managing patient data. ImpediMed's mission is to improve long-term patient outcomes and establish new standards of care through innovative technology.

• Employees 83
• Founded 1999
• Annual Revenue $8318000
• Total Funding $74068800